The holding subsidiary Sinopharm Group Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. (hereinafter referred to as "Sinopharm Zhijun Pingshan") received the Notice of Approval for Supplementary Drug Application approved and issued by the State Pharmaceutical Products Supervision Administration, and agreed to change the marketing license holder of Olmesartan cilexetil (20mg/5mg) to Sinopharm Zhijun Pingshan.
On February 8, 2022, Sinopharm Zhijun Pingshan and Jilin Suntech Pharmaceutical Co., Ltd. (hereinafter referred to as "Jilin Suntech") signed the Drug Marketing License Transfer Contract, and Jilin Suntech transferred the drug marketing license of Olmesartan cilexetil Amlodipine Tablets (20mg/5mg) that it was applying for registration to Sinopharm Zhijun Pingshan, with a total transfer fee of RMB 33.8 million.